tiprankstipranks
The Fly

Arcturus Therapeutics initiated with a Buy at BTIG

Arcturus Therapeutics initiated with a Buy at BTIG

BTIG initiated coverage of Arcturus Therapeutics (ARCT) with a Buy rating and $41 price target Arcturus is a commercial-stage biotechnology company focused on mRNA therapeutics and vaccines with a cash position expected to last into Q1 of 2027, the analyst tells investors in a research note. The firm says that for each of the company’s lead programs, Arcturus recently initiated Phase 2 studies powered to provide significant proof of concept in patients with data expected in the first half of 2025. BTIG sees these catalysts as the major reason to own the stock now. On the vaccine front, the Arcturus platform leverages the attractive properties of self-amplifying mRNA, the analyst adds.

Discover the Best Stocks and Maximize Your Portfolio:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1